Equine encephalitis vaccine is under clinical development by Bavarian Nordic and currently in Phase I for Eastern Equine Encephalitis. According to GlobalData, Phase I drugs for Eastern Equine Encephalitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Equine encephalitis vaccine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Equine encephalitis vaccine overview
Vaccine (MVA-BN WEV) is under development for the prevention of Eastern equine encephalitis, Western equine encephalitis and Venezuelan equine encephalitis. The therapeutic candidate is developed based on MVA-BN (Modified Vaccinia Ankara – Bavarian Nordic) vaccine platform technology.
Bavarian Nordic overview
Bavarian Nordic is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara –Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, COVID-19, respiratory syncytial virus, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.
For a complete picture of Equine encephalitis vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.